Carcinome hépatocellulaire avancé: importance des essais thérapeutiques [Advanced hepatocellular carcinoma: importance of clinical trials]

Détails

ID Serval
serval:BIB_7B026B899673
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Carcinome hépatocellulaire avancé: importance des essais thérapeutiques [Advanced hepatocellular carcinoma: importance of clinical trials]
Périodique
Revue medicale suisse
Auteur⸱e⸱s
Aedo V., Cristina V., Raymond E., Faivre S.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
20/05/2015
Peer-reviewed
Oui
Volume
11
Numéro
475
Pages
1149-1151
Langue
français
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
In hepatocellular carcinoma, sorafenib is the only active medical treatment validated to date. Sorafenib is a targeted therapy mainly blocking tumor vascularisation. Sorafenib is currently used for inoperable or advanced stages of hepatocellular carcinoma, as well for hepatocellular carcinoma recurrence when the disease is diffuse or multifocal. Current clinical trials are designed to identify new antitumor molecules active in hepatocellular carcinoma that could enrich the therapeutic armamentarium in addition to sorafenib.
Mots-clé
Antineoplastic Agents/therapeutic use, Benzenesulfonates/therapeutic use, Carcinoma, Hepatocellular/pathology, Carcinoma, Hepatocellular/therapy, Clinical Trials as Topic/statistics & numerical data, Disease Progression, Humans, Liver Neoplasms/pathology, Liver Neoplasms/therapy, Niacinamide/analogs & derivatives, Patient Selection, Phenylurea Compounds, Sorafenib
Pubmed
Création de la notice
03/04/2023 11:46
Dernière modification de la notice
04/04/2023 6:54
Données d'usage